Compare RCAT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | AGIO |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2017 | 2013 |
| Metric | RCAT | AGIO |
|---|---|---|
| Price | $8.40 | $40.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $20.00 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 10.7M | 1.2M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $17,836,382.00 | ★ $43,011,000.00 |
| Revenue This Year | $271.60 | $76.75 |
| Revenue Next Year | $41.21 | $170.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 79.95 | N/A |
| 52 Week Low | $5.77 | $22.24 |
| 52 Week High | $18.78 | $46.00 |
| Indicator | RCAT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 65.36 |
| Support Level | $8.01 | $39.31 |
| Resistance Level | $8.85 | $43.72 |
| Average True Range (ATR) | 0.76 | 1.76 |
| MACD | -0.15 | 0.30 |
| Stochastic Oscillator | 3.53 | 60.73 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Red Cat's suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.